Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Only the indication claim is directly supported by the provided label text. Most other statements in the AI claims list (e.g., dosing timing, onset/duration specifics, side effect prevalence/category, and U.S. prescription-only/legal purchasing statements) are not supported or not stated in the supplied label excerpts.
Category Scores
Accurate Statements
APIDRA is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.
Label section 1 INDICATIONS AND USAGE: “APIDRA is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.”
Unsupported Statements
Apidra is a rapid-acting insulin used to control high blood sugar in adults with diabetes mellitus.
The provided label excerpts do not state “rapid-acting” in the indication statement and do not specifically characterize its use as controlling “high blood sugar” in adults beyond the general “improve glycemic control.”
Apidra is a rapid-acting insulin used to control high blood sugar in children aged 4 years and older with diabetes mellitus.
The provided label excerpt states adult and pediatric patients with diabetes mellitus, but does not specify age 4 years and older.
Apidra is typically taken before meals or snacks.
The provided label excerpts include administration instructions about inspecting solution and checking labels, but do not specify “before meals or snacks” timing.
Apidra is a synthetic form of human insulin.
The label excerpt under DESCRIPTION states “insulin glulisine is a rapid-acting human insulin analog,” not a “synthetic form of human insulin.”
Apidra works by lowering blood glucose.
The mechanism excerpt says “Insulins lower blood glucose,” and APIDRA is an insulin analog, but the claim as written is not explicitly tied to APIDRA in the provided mechanism excerpt; label directly supports “insulin glulisine” lowering blood glucose. This statement is partially supported but not explicitly mapped to APIDRA in the excerpt provided for mechanism of action. (Rated unsupported/insufficiently specific given audit constraints.)
Apidra begins to work rapidly, usually within 15 minutes of injection.
The provided label excerpts discuss more rapid onset and show meal-related comparisons (e.g., APIDRA given 15 minutes after the start of a meal), but do not provide a “usually within 15 minutes of injection” statement.
Apidra's effects last for 2 to 4 hours.
The provided excerpts include a figure collected up to 6 hours but do not state a “2 to 4 hours” duration of effects.
Apidra helps the body use glucose for energy.
The provided mechanism excerpt focuses on glucose metabolism regulation (peripheral uptake, hepatic inhibition) and does not state “for energy.”
Apidra stops the liver from producing too much glucose.
The mechanism excerpt says insulins inhibit hepatic glucose production, which corresponds to the claim, but the statement attributes specifically to “the liver” in the exact wording; given the explicit label text “inhibiting hepatic glucose production,” this is supported. (Not listed here as unsupported.)
Common side effects of Apidra include hypoglycemia (low blood sugar).
The label lists hypoglycemia as the most common adverse reaction (5.3) and includes hypoglycemia in tables, but the claim specifically says “common side effects.” Label supports hypoglycemia as the most common adverse reaction; however, the provided adverse reaction tables show thresholds (≥5%) and do not state “common side effects” generically. Treated as partially supported but not explicitly “common” in the way claimed.
Common side effects of Apidra include injection site reactions.
Injection site reactions are not listed in the provided adverse reaction tables/excerpts.
Common side effects of Apidra include itching.
Itching is not listed in the provided adverse reaction tables/excerpts.
Severe hypoglycemia can be a serious condition requiring immediate medical attention.
The label states severe hypoglycemia can cause seizures, unconsciousness, may be life-threatening, or cause death; it does not state “requiring immediate medical attention.”
Other potential side effects of Apidra can include swelling.
Peripheral edema is listed in Table 2 (≥5% in pooled studies of adults with type 2 diabetes). The label excerpt uses “Edema peripheral,” not explicitly “swelling.” Not explicitly supported as written.
Other potential side effects of Apidra can include weight gain.
Weight gain is not present in the provided adverse reaction excerpts/tables.
Other potential side effects of Apidra can include changes in vision.
Changes in vision are not present in the provided adverse reaction excerpts/tables.
In the United States, Apidra is a prescription-only medication.
The provided label excerpts do not include regulatory distribution statements (prescription-only status).
In the United States, Apidra cannot be legally purchased online or in person without a valid prescription from a healthcare provider.
The provided label excerpts do not state any legal purchasing or online availability restrictions.
Contradictions
Important Omissions
For any claim about administration timing (e.g., “before meals or snacks”), the label would normally include specific dosing/administration instructions, but the provided label excerpts do not include those details.
Importance:
Moderate
For side effects, the label excerpt provides only selected warnings/precautions and pooled adverse reactions tables; missing is whether specific asserted “common” adverse reactions (injection site reactions, itching, weight gain, vision changes) are present/quantified in the label sections not provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While hypoglycemia risk is supported by the label, several other claims about dosing timing and specific side effects are not supported by the provided prescribing information excerpts. Unsupplied or incorrect guidance (e.g., meal timing, onset/duration, and adverse reaction specifics) could lead to misunderstandings, even though no direct contraindication conflicts are identified from the supplied excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most of the AI’s additional claims (meal/snack timing, onset within 15 minutes, duration 2–4 hours, specific side effect categories, and U.S. prescription/legal purchasing statements) are not supported by the provided FDA label excerpts.
Suggested Improvement
Restrict claims to label-supported statements in the provided text (e.g., indication, mechanism of action elements, and hypoglycemia severity language). Remove or qualify unsupported specifics (age threshold 4+, meal timing, numeric onset/duration, injection site/itching/weight gain/vision changes, and U.S. prescription/legal purchasing statements) unless supported by additional label sections not included in the prompt.